Anagliptin prevented interleukin 1β (IL-1β)-induced cellular senescence in vascular smooth muscle cells through increasing the expression of sirtuin1 (SIRT1)

Juan Zhao, Xinrong He, Mei Zuo, Xinguo Li, and Zhiming Sun

Abstract

Vascular smooth muscle cell senescence plays a pivotal role in the pathogenesis of atherosclerosis. Anagliptin is a novel dipeptidyl peptidase-4 (DPP-4) inhibitor for the treatment of hyperglycemia. Recent progress indicates that DPP-4 inhibitors show a wide range of cardiovascular benefits. We hypothesize that Anagliptin plays a role in vascular smooth muscle cell senescence and this may imply its modulation of atherosclerosis. Here, the beneficial effect of Anagliptin against interleukin 1β (IL-1β)-induced cellular senescence in vascular smooth muscle cells was studied to learn the promising therapeutic capacity of Anagliptin on atherosclerosis. Firstly, we found that Anagliptin treatment ameliorated the elevated secretions of tumor necrosis factor-α (TNF-α), interleukin 6 (IL-6), and macrophage chemoattractant protein-1 (MCP-1). Secondly, our findings indicate that exposure to IL-1β reduced telomerase activity from 26.7 IU/L to 15.8 IU/L, which was increased to 20.3 and 24.6 IU/L by 2.5 and 5 μM Anagliptin, respectively. In contrast, IL-1β stimulation increased senescence-associated β-galactosidase (SA-β-gal) staining to 3.1-fold compared to the control group. It was then reduced to 2.3- and 1.6-fold by Anagliptin dose-dependently. Thirdly, Anagliptin dramatically reversed the upregulated p16, p21, and downregulated sirtuin1 (SIRT1) in IL-1β-treated vascular smooth muscle cells. Lastly, the protective effect of Anagliptin against cellular senescence in vascular smooth muscle cells was abolished by silencing of SIRT1. In conclusion, Anagliptin protects vascular smooth muscle cells from cytokine-induced senescence, and the action of Anagliptin in vascular smooth muscle cells requires SIRT1 expression.

Introduction

Cell senescence is defined as the permanently irreversible stagnation of the cell cycle with the specific characteristics of cell morphology, gene expression, and cellular metabolism, which is different from cell arrest and cell apoptosis [1]. As the investigations on cell senescence further develop, several characteristics have been proven to be useful in determining the state of cell senescence. Firstly, the morphology of cells under the state of cell senescence tends to be flat and wide. In addition, a series of changes to gene expression, chromatin structure, cellular function, and cell phenotypes, such as the activation of SA-β-Gal, the up-regulation of cell cycle regulators, the...
shortening of the telomere, DNA damage, and the formation of the senescence-associated secretory phenotype (SASP) and senescence-associated heterochromatin foci (SAHF) [2]. It is reported that the cell senescence of vascular smooth muscle cells, is the early symbol of atherosclerosis, which is the basis of multiple types of cardiovascular diseases [3]. As the pathogenesis of atherosclerosis develops, vascular smooth muscle cells migrate to the tunica intima and accumulate around necrotic foam cells to form fibrous caps, which further contributes to the development of atherosclerotic plaques [4,5]. Inflammatory factors, such as IL-1β, are known to induce the state of cell senescence in cells [6,7]. Oxidative stress-induced premature senescence of vascular smooth muscle cells (VSMCs) has been reported in both in vitro and in vivo experiments [8]. VSMC senescence is associated with the instability of plaque formation and repair after rupture, and the understanding of VMSC senescence may provide evidence of targeted treatment in atherosclerosis [9]. Several cell cycle regulators such as p53, p21, and p16 are essential landmarks of senescence [10]. P21 is the downstream target gene of p53 and can be induced by it. In addition, p21 is an inhibitor of the cell cycle and arrests it at the G1 phase by inhibiting cyclin E [11]. The transformation from the G1 phase to the S phase is regarded as one of the characteristics of cell senescence [12]. As an inhibitor of cyclin-dependent kinases (CDK), p16 suppresses the activity of CDK4/6 by binding with cyclin D, further blocking the progression of the cell cycle [13]. Recently, it has been reported that SIRT1 could inhibit the transcription and activation of downstream genes of p53 by directly inactivating p53, indicating a potential regulatory effect of SIRT1 on cell senescence [14]. In addition, SIRT1 is reported to exert anti-oxidative and anti-apoptotic properties, it is significantly down-regulated in atherosclerotic tissues and its expression is negatively related to the level of total cholesterol and low-density lipoprotein [15]. Therefore, targeting cell senescence of vascular smooth muscle cells has become an important strategy for the treatment of atherosclerosis.

Anagliptin (Figure 1a) is a novel compelling and specific inhibitor of dipeptidyl peptidase-4 (DPP-4) first approved for hyperglycemia therapy in Japan in 2012 [16]. Results of clinical trials revealed that Anagliptin exerted promising anti-diabetic effects, which could be enhanced by combination with acarbose [17,18]. Recently, potential therapeutic effects of Anagliptin against atherosclerosis have been reported. Hirano [19] claimed that in cholesterol-fed rabbits, the macrophage infiltration, and atherosclerosis in aortic and coronary arteries were significantly ameliorated by treatment with Anagliptin. Furthermore, Ervinn reported that in apoE-deficient mice, the proliferation of vascular smooth muscles and monocyte inflammation were both significantly suppressed and atherosclerosis was greatly alleviated by the administration of Anagliptin [20]. In addition, Anagliptin is reported to activate SIRT1 to ameliorate high glucose-induced endothelial dysfunction [21]. However, it’s unknown whether Anagliptin exerts a beneficial action against cellular senescence. Here, the protective effect of Anagliptin on IL-1β-induced cellular senescence in vascular smooth muscle cells was evaluated to judge whether Anagliptin possesses promising potential in the management of atherosclerosis.

Materials and methods

Cell culture and treatments

This study was performed in accordance with the principles of the World Medical Association Declaration of Helsinki for medical research using human-derived cells. Experimental protocols were approved by the Ethical Committee of Yan’an University. Human vascular smooth muscle cells (hVSMCs) were obtained from Guandao Biological Engineering (Shanghai, China) and cultured in a Dulbecco’s Modified Eagle Medium (DMEM) supplied with 10% fetal bovine serum (FBS) in 5% CO2 at 37°C. The treatment reagent IL-1β was purchased from R&D Systems (#201-LB), and Anagliptin was obtained from Sigma-Aldrich (#4943). To test the cytotoxicity of Anagliptin, hVSMCs were treated with a series of Anagliptin ranging from 0.1 to 50 μM. For all other experiments, cells were challenged with IL-1β (10 ng/mL) [22] or Anagliptin (2.5, and 5 μM) [20] for 24 hours. The cell treatment conditions were based on previous publications.
After incubation for 30 minutes, OD at 490 nm was measured after eliminating the reaction.

**Real-time PCR analysis**

In brief, an RNA isolation kit (Takara, Tokyo, Japan) was applied to isolate total RNAs from hVSMCs, followed by being transcribed into cDNA according to the instruction of the qRT-PCR mRNA Detection Kit (Takara, Tokyo, Japan). Subsequently, the Lightcycler 480 Detection System (Roche, Basel, Switzerland) was used to perform real-time PCR, with GAPDH taken as the internal control for normalization. The cycle times were recorded for the calculation of target genes according to the $2^{-\Delta\Delta Ct}$ method. The following primers were used:

$$\text{MCP-1 (F: 5'}^′\text{-AGAATCACCACGAGAAATGTCC-3'}, \text{R: 5'}^′\text{-TCCTGAACCCACTTCTTGAG-3'); IL-6 (F: 5'}^′\text{-TGTTCTTTTGGAGTTTGAGGT-3'}, \text{R: 5'}^′\text{-AGGTTCCTGAACAGAAGAAG-3'); TNF-α (5'}^′\text{-CTCTTCTGCTGCTGCTTGG-3'}, 5'}^′\text{-ATGGGCTACAGGCTTGGACT-3'); p16 (5'}^′\text{-CCTAACACGCACCATAGTGA-3'}, 5'}^′\text{-ACACGCACGAGGAAATGC-3'), 5'}^′\text{-TGGAGCTTCAAGGCTTTGACT-3'); GAPDH (5'}^′\text{-TGGAGCTTCAAGGCTTTGACT-3'}, 5'}^′\text{-TGGAGCTTCAAGGCTTTGACT-3').}$$

**Western blot analysis**

The total proteins were isolated from the treated hVSMCs using the lysis buffer, and quantified using the bicinchoninic acid (BCA) kit (Beyotime, Shanghai, China). Subsequently, the proteins were run on 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and further transferred to the polyvinylidene fluoride (PVDF) membrane (Bio-Rad, USA). After 3 washes with PBST buffer, the membrane was incubated with the primary antibody against p16, p21, SIRT1, and β-actin overnight in a cold room and incubated with HRP-conjugated secondary antibody (1:2000, CST, Boston, USA) at room temperature for 1.5 hours. Lastly, the
membranes were exposed to an ECL detection system (CST, Boston, USA).

**Enzyme-linked immunosorbent assay (ELISA) assay**

The concentrations of TNF-α, IL-6, and MCP-1 in the supernatant of treated hVSMCs were detected using the ELISA commercial kits (R&D Systems Europe, Abington, UK). The following Quantikine ELISA kits were purchased: IL-6 (#D6050), TNF-α (#PDTA00D), and MCP-1(#DCP00). TNF-α, IL-6, and MCP-1 were measured as per the detailed procedure described previously [23].

**Telomerase activity**

The CHAPS buffer was used to lyse the treated hVSMCs, followed by centrifugation at 15,000 × g for 30 minutes and quantifying the concentration of total proteins using the BCA kit (Beyotime, Shanghai, China). The TeloTAGGG Telomerase PCR ELISA Plus Kit (Roche, Basel, Switzerland) was used to measure the telomerase activity. The TRAP-PCR reaction system contained 0.5 mg of each sample and 10 pM of each primer, followed by quantification using RT-PCR assay.

**Senescence-associated β-galactosidase (SA-β-gal) staining**

The Senescence Detection kit (Beyotime, Shanghai, China) was used. Briefly, cells were washed with PBS buffer and fixed using 2% paraformaldehyde for 5 min, followed by washing and incubated at 37°C in the absence of CO₂ in fresh SA-β-gal staining solution. Lastly, the percentage of SA-β-gal positive blue cells was counted after being photographed.

**Statistical analysis**

Analysis of Variance (ANOVA) with Tukey’s Multiple Comparison post-hoc test was used to compare the difference among groups. P < 0.05 was considered statistically significant.

**Results**

We aimed to investigate whether Anagliptin possesses a protective effect against IL-1β-induced insults in VMSCs. We demonstrated that Anagliptin prevented cellular senescence by reducing SA-β-gal but increasing telomerase activity in IL-1β-challenged VMSCs. Mechanistically, we found that this effect was mediated by SIRT1.

**The effects of Anagliptin on cell viability of vascular smooth muscle cells**

To test the cellular response to Anagliptin in IL-1β treated VMSCs, we performed the dose-response experiment. 10 ng/ml of IL-1β was used to treat VMSCs for 24 hours as described before [22]. The concentration of Anagliptin was based on previous report [23] and our test results. To test the cytotoxicity, cells were stimulated with Anagliptin at the concentrations of 0.1, 0.25, 0.5, 2.5, 5, 25, and 50 μM for 24 hours. No obvious difference was observed in the cell viability when Anagliptin was lower than 5 μM (Figure 1b). However, the cell viability decreased greatly as the concentration of Anagliptin was elevated to 25, and 50 μM. Similarly, the release of LDH was kept around 5% when Anagliptin was lower than 5 μM but was promoted to 9.5% and 16.5% by the introduction of 25, and 50 μM Anagliptin, respectively. Therefore, 2.5, and 5 μM were used as the incubation concentrations of Anagliptin in the subsequent experiments.

**Anagliptin reduced IL-1β-induced expression of pro-inflammatory cytokines in vascular smooth muscle cells**

The expressions of TNF-α, IL-6, and MCP-1 were remarkably increased by IL-1β and then suppressed by the introduction of Anagliptin (Figure 2a-c). We further detected the protein concentrations of TNF-α, IL-6, and MCP-1. The secretion of TNF-α was increased from 86.3 to 255.4 pg/mL by IL-1β then inhibited to 196.7 and 166.2 pg/mL by 2.5 and 5 μM Anagliptin, respectively. In addition, the secretions of IL-6 (Figure 2e) released in the control, IL-1β, 2.5 μM Anagliptin, and 5 μM Anagliptin groups were
135.1, 436.9, 337.5, and 273.8 pg/mL respectively. Lastly, the secretion of MCP-1 was elevated from 97.3 to 312.8 pg/mL by IL-1β but reduced to 246.7 and 172.5 pg/mL by the introduction of 2.5, and 5 μM Anagliptin, respectively.

**Anagliptin prevented IL-1β-induced cellular senescence**

The telomerase activity was reduced from 26.7 IU/L to 15.8 IU/L by IL-1β but increased to 20.3 and 24.6 IU/L by 2.5, and 5.0 μM Anagliptin (Figure 3), respectively, indicating that Anagliptin remarkably attenuated the cellular senescence in vascular smooth muscle cells caused by IL-1β. We confirmed the effect of Anagliptin on cell senescence by performing the SA-β-gal staining assay. As expected, the activity of SA-β-gal was elevated by IL-1β but suppressed by the introduction of Anagliptin (Figure 4), confirming the beneficial effect of Anagliptin on IL-1β-induced cell senescence in vascular smooth muscle cells.

**Anagliptin reduced the expressions of p16 and p21**

To explore the potential mechanism of Anagliptin in vascular smooth cells, the expression levels of
cell senescence-related proteins were determined. The expressions of p16 and p21 were markedly increased by IL-1β but greatly inhibited by Anagliptin (Figure 5). In addition, the downregulated SIRT1 (Figure 6) in IL-1β-treated vascular smooth muscle cells was upregulated by the introduction of Anagliptin.

**Silencing of SIRT1 abolished the beneficial effects of Anagliptin against cellular senescence in vascular smooth muscle cells**

To further verify that the effects of Anagliptin on cell senescence were related to the upregulation of SIRT1, the expression of SIRT1 was silenced by transfection with SIRT1 siRNA. SIRT1 was obviously declined in siRNA-treated cells (Figure 7a), indicating that the knockdown of SIRT1 in vascular smooth muscle cells was successfully achieved. Interestingly, telomerase activity was reduced from 25.8 IU/L to 15.1 IU/L by IL-1β, and then increased to 23.9 IU/L by the treatment with 5 µM Anagliptin (Figure 7b). In Anagliptin-treated SIRT1 knockdown vascular smooth muscle cells, the telomerase activity was further decreased to 16.8 IU/L. In addition, the elevated activity of SA-β-gal (Figure 7c) induced by IL-1β was significantly suppressed by Anagliptin, reversed by the knockdown of SIRT1. These data indicate that Anagliptin might exert beneficial actions against IL-1β-induced cell senescence through up-regulation of SIRT1.

**Discussion**

Telomere length is negatively related to the risk of cardiovascular diseases [24]. Compared to normal vascular wall cells and circulating endothelial progenitor cells [25], more significant shortened telomeres are observed in vascular smooth muscle cells [24] and endothelial cells [26] in atherosclerotic plaque. In addition to physiological senescence-related biological changes, the cells in the premature senescence state are accompanied by elevated expressions of inflammatory factors, further aggravating the damage to the tissues [27]. In this study, the *in vitro* cell senescence model was constructed on vascular smooth muscle cells by incubating the cells with IL-1β, which was verified by the decreased telomerase activity, elevated SA-β-gal, and increased secretion of inflammatory factors. By introducing optimized dosages of Anagliptin, the state of cell senescence and excessively released inflammatory factors in vascular smooth muscle
cells were significantly reversed, indicating that Anagliptin might exert a promising anti-senescence effect against IL-1β-induced vascular smooth muscle cells.

P16 is encoded by INK4a/ARF located on 9p21, the N-terminal of which has the homologous structure to cyclin D. P16 impacts the phosphorylation of CDK4/6 retinoblastoma protein and the activation of downstream transcriptional factor E2F by competitively binding with cyclin D, arresting the cell cycle at the G1 phase [28]. Recently, p16 is reported to inhibit the cell cycle by inducing the degradation of the phosphorylated CDK4/6 retinoblastoma protein [29]. P53 is a stress protein and is rapidly upregulated when the cells are under stimulation, suppressing the activity of cyclinA/E-CDK2, inhibiting the phosphorylation of CDK4/6 retinoblastoma protein, and blocking the progression of the cell cycle by activating p21 [30]. Han reported that p16 could enhance the stability of p21 and that p16 could be activated by the interaction between p21 and Sp1, which contribute to the inhibition of the cell cycle synergistically [31]. Here, by the stimulation, the cell senescence was induced in vascular smooth muscle cells, accompanied by the upregulation of

Figure 5. Anagliptin prevented IL-1β-induced p16 and p21. (a). mRNA of p16 and p21; (b). Protein of p16 and p21 (****, P < 0.0001 vs. vehicle group, ##, ###, P < 0.1, 0.001 vs. IL-1β group).

Figure 6. Anagliptin restored IL-1β-induced expression of SIRT1. (a). mRNA of SIRT1; (b). Protein of SIRT1 (****, P < 0.0001 vs. vehicle, ##, ###, P < 0.1, 0.001 vs. IL-1β).
Anagliptin will exert significantly, inhibiting p16, p21, p53, and forkhead box protein O (FOXO) [32]. Xia [33] reported that the activation of SIRT1 could suppress the expression of p16. In addition, the activation of the p53/p21 signaling pathway could be inhibited by SIRT1 by inducing the deacetylation on p21 or p53 [34,35]. We reported that the downregulated expression level of SIRT1 in IL-1β-challenged vascular smooth muscle cells was significantly reversed by Anagliptin, indicating that Anagliptin might regulate the p16 and p21 signaling pathway by activating SIRT1. We further confirmed the mechanism by establishing SIRT1-knockdown vascular smooth muscle cells. In our future work, more detailed investigations, such as detecting the deacetylation level of p21 and p53, will be conducted to better understand the regulatory effects of Anagliptin on SIRT1 and its downstream pathway.

The senescence of VSMCs accompanied by the gained senescence-associated secretory phenotype (SASP) could lead to vascular inflammation, hence the loss of vascular function [9]. Our data suggest Anagliptin effectively suppressed the production of key pro-inflammatory cytokines (TNF-α, IL-6, and MCP-1) and the expressions of senescence pathways (p53/p21 and p16), implying its multiple regulation ability on vascular smooth muscles. As a result, the presence of Anagliptin attenuated the senescent phenotype induced by IL-1β. Mechanistically, our knockdown experiment demonstrates that the action of Anagliptin is dependent on the activity of SIRT-1, implying that SIRT-1 is an essential element of the Anagliptin regulator upstream.

A recent study shows that selective elimination of senescent cells by silencing key regulators in mice can improve age-related chronic diseases [36]. It is optimistic that the targeted suppression of vascular cells could have the potential to slow down the progression of atherosclerosis. Previous works show the inhibition of the senescence pathway in vascular smooth muscle cells appears to affect atherosclerotic plaque vulnerability [37–39]. DPP-4 inhibitors have shown many beneficial effects in cardiovascular diseases [40,41]. It is possible that this class of drug could have a role in alleviating vascular smooth muscle cells senescence in hyperlipidemia conditions. Also, we have to mention the limitation of the current study. Although our study shows strong evidence that inhibition of the DPP4 pathway by
Anagliptin could attenuate vascular smooth muscle cells senescence in cultured cells, the underlying mechanism remains incompletely understood. We show that SIRT-1 could be a central mediator of Anagliptin action, however, the detailed molecular pathways need to be investigated. Also, future in vivo experiments are warranted to validate the findings.

**Conclusion**

To sum up, our data revealed that Anagliptin prevented IL-1β-induced cellular senescence in vascular smooth muscle cells by up-regulating SIRT1. Thus, we concluded that the DPP-4 inhibitor Anagliptin has a protective role in vascular smooth muscle cells.

**Acknowledgements**

This study is supported by the “fourth people’s Hospital of Shaanxi Province”.

**Disclosure statement**

No potential conflict of interest was reported by the author(s).

**ORCID**

Zhiming Sun [http://orcid.org/0000-0002-0914-5287](http://orcid.org/0000-0002-0914-5287)

**References**

[1] Sikora E, Bielak-Zmijewska A, Mosieniak G. What is and what is not cell senescence. Postepy Biochem. 2018;64:110–118.
[2] Bernardes de Jesus B, Blasco MA. Assessing cell and organ senescence biomarkers. Circ Res. 2012;111:97–109.
[3] Bennett MR, Sinha S, Owens GK. Vascular Smooth Muscle Cells in Atherosclerosis. Circ Res. 2016;118:692–702.
[4] Andres V. Vitamin D puts the brakes on angiotensin II-induced oxidative stress and vascular smooth muscle cell senescence. Atherosclerosis. 2014;236:444–447.
[5] Grootaert MO, Da Costa Martins PA, Bitsch N, et al. Defective autophagy in vascular smooth muscle cells accelerates senescence and promotes neointima formation and atherogenesis. Autophagy. 2015;11:2014–2032.
[6] Chai B, Zheng ZH, Liao X, et al. The protective role of omentin-1 in IL-1beta-induced chondrocyte senescence. Artif Cells Nanomed Biotechnol. 2020;48:8–14.
[7] Huang X, You Y, Yi X, et al. p-Coumaric Acid Attenuates IL-1beta-Induced Inflammatory Responses and Cellular Senescence in Rat Chondrocytes. Inflammation. 2020;43(2):619–628.
[8] Matthews C, Gorenne I, Scott S, et al. Vascular smooth muscle cells undergo telomere-based senescence in human atherosclerosis: effects of telomerase and oxidative stress. Circ Res. 2006;99(2):156–164.
[9] Grootaert MO, Moulis M, Roth L, et al. Vascular smooth muscle cell death, autophagy and senescence in atherosclerosis. Cardiovasc Res. 2018;114(4):622–634.
[10] Fei C, Zhao Y, Guo J, et al. Senescence of bone marrow mesenchymal stromal cells is accompanied by activation of p53/p21 pathway in myelodysplastic syndromes. Eur J Haematol. 2014;93(6):476–486.
[11] Minella AC, Swanger J, Bryant E, et al. p53 and p21 form an inducible barrier that protects cells against cyclin E-cdk2 deregulation. Curr Biol. 2002;12(21):1817–1827.
[12] Choi MR, Kim SH, Ohn T, et al. Resveratrol relieves hydrogen peroxide-induced premature senescence associated with SIRT1 in human mesenchymal stem cells. Mol Cell Toxicol. 2014;10:330–341.
[13] Freedman DA, Folkman J, CDK2 translational down-regulation during endothelial senescence. Exp Cell Res. 2005;307(1):118–130.
[14] Ye Z, Fang J, Dai S, et al. MicroRNA-34a induces a senescence-like change via the down-regulation of SIRT1 and up-regulation of p53 protein in human esophageal squamous cancer cells with a wild-type p53 gene background. Cancer Lett. 2016;370:216–221.
[15] Gardner PJ, Joshi L, Lee RW, et al. SIRT1 activation protects against autoimmune T cell-driven retinal disease in mice via inhibition of IL-2/Stat5 signaling. J Autoimmun. 2013;42:117–129.
[16] Dong C, Yang H, Wang Y, et al. Anagliptin stimulates osteoblastic cell differentiation and mineralization. Biomed Pharmacother. 2020;129:109796.
[17] Hamasaki H, Yanai H. The development of angioedema in a patient with type 2 diabetes due to a novel dipeptidyl peptidase-IV inhibitor, anagliptin. Int J Cardiol. 2013;168:e106.
[18] Nishio S, Abe M, Ito H. Anagliptin in the treatment of type 2 diabetes: safety, efficacy, and patient acceptability. Diabetes Metab Syndr Obes. 2015;8:163–171.
[19] Hirano T, Yamashita S, Takahashi M, et al. Anagliptin, a dipetidyl peptidase-4 inhibitor, decreases macrophage infiltration and suppresses atherosclerosis in aortic and coronary arteries in cholesterol-fed rabbits. Metabolism. 2016;65:893–903.
[20] Ervinna N, Mita T, Yasunari E, et al. Anaglaptin, a DPP-4 inhibitor, suppresses proliferation of vascular smooth muscles and monocyte inflammatory reaction and attenuates atherosclerosis in male apo E-deficient mice. Endocrinology. 2013;154(3):1260–1270.

[21] Jiang T, Jiang D, Zhang L, et al. Anaglaptin ameliorates high glucose- induced endothelial dysfunction via suppression of NLRP3 inflammasome activation mediated by SIRT1. Mol Immunol. 2019;107:54–60.

[22] Mach F, Schönbeck U, Sukhova GK, et al. CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis. Proc Natl Acad Sci U S A. 1997;94(5):1931–1936.

[23] Purschwitz K, Rassoul F, Reuter W, et al. Soluble leukocyte adhesion molecules in vegetarians of various ages. Z Gerontol Geriatr. 2001;34(6):476–479.

[24] Panayiotou AG, Nicolaides AN, Griffin M, et al. Leukocyte telomere length is associated with measures of subclinical atherosclerosis. Atherosclerosis. 2010;211:176–181.

[25] Uryga AK, Bennett MR. Ageing induced vascular smooth muscle cell senescence in atherosclerosis. J Physiol. 2016;594:2115–2124.

[26] Ogami M, Ikura Y, Ohsawa M, et al. Telomere shortening in human coronary artery diseases. Arterioscler Thromb Vasc Biol. 2004;24:546–550.

[27] Rodier F, Coppe JP, Patil CK, et al. Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion. Nat Cell Biol. 2009;11:973–979.

[28] Stein GH, Drullinger LF, Soulard A, et al. Differential roles for cyclin-dependent kinase p21 and p16 in the mechanisms of senescence and differentiation in human fibroblasts. Mol Cell Biol. 1999;19:2109–2117.

[29] Haferkamp S, Becker TM, Scurr LL, et al. p16INK4a-induced senescence is disabled by melanoma-associated mutations. Aging Cell. 2008;7(5):733–745.

[30] Lin CP, Lin CS, Lin HH, et al. Bergapten induces G1 arrest and pro-apoptotic cascade in colorectal cancer cells associating with p53/p21/PTEN axis. Environ Toxicol. 2019;34(3):303–311.

[31] Han XL, Wu FG, Zhang ZY, et al. Posttranscriptional induction of p21Waf1 mediated by ectopic p16INK4 in human diploid fibroblast. Chin Med J (Engl). 2007;120:405–409.

[32] Satoh A, Stein L, Imai S. The role of mammalian sirtuins in the regulation of metabolism, aging, and longevity. Handb Exp Pharmacol. 2011;206:125–162.

[33] Xia X, Guo J, Lu F, et al. SIRT1 Plays a Protective Role in Intervertebral Disc Degeneration in a Puncture-induced Rodent Model. Spine (Phila Pa 1976). 2015;40:E515–2.

[34] Li B, Li M, Li X, et al. Sirt1-inducible deacetylation of p21 promotes cardiomyocyte proliferation. Aging (Albany NY). 2019;11:12546–12567.

[35] Gu X, Wang Z, Gao J, et al. SIRT1 suppresses p53-dependent apoptosis by modulation of p21 in osteoblast-like MC3T3-E1 cells exposed to fluoride. Toxicol In Vitro. 2019;57:28–38.

[36] Cheng QS, Zhang M, Zhang MS, et al. Long non-coding RNA LOC285194 regulates vascular smooth muscle cell apoptosis in atherosclerosis. Bioengineered. 2020;11(1):53–60.

[37] Li Q, Xiao ZZ, Wang YS, et al. Alterations of long non-coding RNA and mRNA profiles associated with extracellular matrix homeostasis and vascular aging in rats. Bioengineered. 2021;12(1):832–843.

[38] Kunieda T, Minamino T, Nishi J, et al. II induces premature senescence of vascular smooth muscle cells and accelerates the development of atherosclerosis via a p21-dependent pathway. Circulation. 2006 Aug 29;114(9):953–960.

[39] Bennett MR, Macdonald K, Chan SW, et al. Cooperative interactions between RB and p53 regulate cell proliferation, cell senescence, and apoptosis in human vascular smooth muscle cells from atherosclerotic plaques. Circ Res. 1998 Apr 6;82(6):704–712.

[40] Papagianni M, Tzimolakos K. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors. Hippokratia. 2015 Jul-Sep;19(3):195–199.

[41] Rankovic M, Jeremic N, Srejovic I, et al. Dipeptidyl peptidase-4 inhibitors as new tools for cardioprotection. Heart Fail Rev. 2021 Mar;26(2):437–450.